ARCHIVES

Phase III Regorafenib Trial Meets PFS Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 35 No. 6 | June 29, 2012

Download PDF Visit The Full Archive

Related Articles

Legacy CEO Cheryl Healton says foundation could serve as funder for research on “potentially reduced-exposure products.”

October 29, 2004

NIH Advisors Urge Overhaul Of Peer Review System.

March 7, 2008

In Brief: AACR To Have Fur Symposia, Including One With ASCO; McConnell Names TRTP Director

March 21, 1986

Pas Available; Alternative Medicine

January 21, 1994

Estrogen Can Benefit Women With Metastatic Breast Cancer

January 30, 2009

CCIRC Members Now Feel At Home In DCT

March 3, 1978